CO2025012255A2 - Antagonista del receptor de tipo 2 de melanocortina - Google Patents

Antagonista del receptor de tipo 2 de melanocortina

Info

Publication number
CO2025012255A2
CO2025012255A2 CONC2025/0012255A CO2025012255A CO2025012255A2 CO 2025012255 A2 CO2025012255 A2 CO 2025012255A2 CO 2025012255 A CO2025012255 A CO 2025012255A CO 2025012255 A2 CO2025012255 A2 CO 2025012255A2
Authority
CO
Colombia
Prior art keywords
receptor antagonist
melanocortin
melanocortin type
type
receptor
Prior art date
Application number
CONC2025/0012255A
Other languages
English (en)
Spanish (es)
Inventor
Masaki Ogino
Shigemitsu Matsumoto
Naoyoshi Noguchi
Hideto Fukushi
Satoshi Sasaki
Minoru Ikoma
Tsuyoshi Maekawa
Hideki Hirose
Ryoma Hara
Kohei Asano
Koji Watanabe
Shizuo Kasai
Original Assignee
Scohia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scohia Pharma Inc filed Critical Scohia Pharma Inc
Publication of CO2025012255A2 publication Critical patent/CO2025012255A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2025/0012255A 2023-05-16 2025-09-10 Antagonista del receptor de tipo 2 de melanocortina CO2025012255A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023080580 2023-05-16
PCT/JP2024/017921 WO2024237266A1 (ja) 2023-05-16 2024-05-15 メラノコルチン２型受容体アンタゴニスト

Publications (1)

Publication Number Publication Date
CO2025012255A2 true CO2025012255A2 (es) 2025-09-18

Family

ID=93519713

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2025/0012255A CO2025012255A2 (es) 2023-05-16 2025-09-10 Antagonista del receptor de tipo 2 de melanocortina

Country Status (13)

Country Link
EP (1) EP4714953A1 (https=)
JP (1) JPWO2024237266A1 (https=)
KR (1) KR20260009350A (https=)
CN (1) CN120858097A (https=)
AR (1) AR132690A1 (https=)
AU (1) AU2024273541A1 (https=)
CL (1) CL2025003547A1 (https=)
CO (1) CO2025012255A2 (https=)
IL (1) IL324502A (https=)
JO (1) JOP20250278A1 (https=)
MX (1) MX2025013542A (https=)
TW (1) TW202509036A (https=)
WO (1) WO2024237266A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL360855A1 (en) * 2000-06-28 2004-09-20 Pfizer Products Inc. Melanocortin receptor ligands
AU2019280689B2 (en) 2018-06-05 2024-09-05 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US12479825B2 (en) * 2019-11-07 2025-11-25 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
JP7734571B2 (ja) 2021-11-30 2025-09-05 株式会社日立製作所 プロセスモデル構築システム、プロセスモデル構築方法

Also Published As

Publication number Publication date
JPWO2024237266A1 (https=) 2024-11-21
EP4714953A1 (en) 2026-03-25
CL2025003547A1 (es) 2026-02-20
AR132690A1 (es) 2025-07-23
IL324502A (en) 2026-01-01
KR20260009350A (ko) 2026-01-19
TW202509036A (zh) 2025-03-01
CN120858097A (zh) 2025-10-28
MX2025013542A (es) 2025-12-01
AU2024273541A1 (en) 2025-11-06
JOP20250278A1 (ar) 2025-11-09
WO2024237266A1 (ja) 2024-11-21

Similar Documents

Publication Publication Date Title
CO2020001879A2 (es) Compuesto heterocíclico y su uso
CL2021001973A1 (es) Compuesto heterocíclico y su uso.
MX2022016212A (es) Profármacos de tripamina.
MX2018009494A (es) Compuestos de piperidina sustituidos y su uso.
ECSP20035590A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
CL2018002516A1 (es) Inhibidores de mcl-1 indólicos sustituidos.
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
CR20170092A (es) Compuestos y composiciones como inhibidores de quinasa raf
CO2020007156A2 (es) Derivado de amino-metil piperidina como inhibidor de quinasa
MX2019011783A (es) Inhibidores de ip6k.
UY31781A (es) Derivados de iminopiridina y su uso
CU20200038A7 (es) Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3
CO2025005865A2 (es) Compuesto heterocíclico
CL2025001563A1 (es) Compuesto heterocíclico y uso del mismo
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.
CO2025012255A2 (es) Antagonista del receptor de tipo 2 de melanocortina
MX2020010667A (es) Profarmacos de desoxinucleosidos para el tratamiento de enfermedades causadas por reservas desequilibradas de nucleotidos.
MX2017005271A (es) Compuestos de nargenicina y sus usos como agentes antibacterianos.
CO2019012270A2 (es) Compuesto heterocíclico
CO2025012357A2 (es) Compuestos heterocíclicos macrocíclicos y sus usos
CO2019012295A2 (es) Compuesto heterocíclico
UY36363A (es) Compuesto heterocíclico fusionado
MX2023003698A (es) Compuesto biciclico que contiene nitrogeno y pirimidina.
UY35603A (es) Compuesto heterocíclico